This is a preview of subscription content, log in via an institution to check access.
Notes
The study was sponsored by Astellas Pharma Europe Ltd.
Reference
Watt M, et al. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany. Infection : 9 Apr 2016. Available from: URL: http://doi.org/10.1007/s15010-016-0894-y
Rights and permissions
About this article
Cite this article
Fidaxomicin cost effective in CDI with high recurrence risk. PharmacoEcon Outcomes News 751, 13 (2016). https://doi.org/10.1007/s40274-016-2973-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2973-9